97 related articles for article (PubMed ID: 29608744)
1. SECOND CANCER RISK FROM RADIATION THERAPY FOR COMMON SOLID TUMORS DIAGNOSED IN REPRODUCTIVE-AGED FEMALES.
Mazonakis M; Kachris S; Damilakis J
Radiat Prot Dosimetry; 2018 Dec; 182(2):208-214. PubMed ID: 29608744
[TBL] [Abstract][Full Text] [Related]
2. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
3. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
Mazonakis M; Lyraraki E; Damilakis J
Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
[TBL] [Abstract][Full Text] [Related]
4. Risk of contralateral breast and ipsilateral lung cancer induction from forward-planned IMRT for breast carcinoma.
Mazonakis M; Stratakis J; Lyraraki E; Damilakis J
Phys Med; 2019 Apr; 60():44-49. PubMed ID: 31000085
[TBL] [Abstract][Full Text] [Related]
5. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer.
Donovan EM; James H; Bonora M; Yarnold JR; Evans PM
Med Phys; 2012 Oct; 39(10):5814-24. PubMed ID: 23039620
[TBL] [Abstract][Full Text] [Related]
6. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.
Kourinou KM; Mazonakis M; Lyraraki E; Papadaki HΑ; Damilakis J
Phys Med; 2019 Jan; 57():100-106. PubMed ID: 30738513
[TBL] [Abstract][Full Text] [Related]
7. Estimation of second cancer risk after radiotherapy for rectal cancer: comparison of 3D conformal radiotherapy and volumetric modulated arc therapy using different high dose fractionation schemes.
Zwahlen DR; Bischoff LI; Gruber G; Sumila M; Schneider U
Radiat Oncol; 2016 Nov; 11(1):149. PubMed ID: 27832799
[TBL] [Abstract][Full Text] [Related]
8. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2018 Oct; 45(10):4775-4782. PubMed ID: 30105825
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for non-malignant shoulder syndrome: Is there a risk for radiation-induced carcinogenesis?
Mazonakis M; Lyraraki E; Tzedakis A; Damilakis J
Phys Med; 2017 Nov; 43():73-78. PubMed ID: 29195566
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Mazonakis M; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2015 Nov; 42(11):6309-16. PubMed ID: 26520723
[TBL] [Abstract][Full Text] [Related]
11. Lifetime attributable risk of radiation induced second primary cancer from scattering and scanning proton therapy - A model for out-of-field organs of paediatric patients with cranial cancer.
Dell'Oro M; Short M; Wilson P; Peukert D; Hua CH; Merchant TE; Bezak E
Radiother Oncol; 2022 Jul; 172():65-75. PubMed ID: 35504365
[TBL] [Abstract][Full Text] [Related]
12. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
13. Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose.
Schneider U; Zwahlen D; Ross D; Kaser-Hotz B
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1510-5. PubMed ID: 15817357
[TBL] [Abstract][Full Text] [Related]
14. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma.
Mazonakis M; Berris T; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2014 May; 41(5):051702. PubMed ID: 24784368
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
16. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
[TBL] [Abstract][Full Text] [Related]
17. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
[TBL] [Abstract][Full Text] [Related]
18. Risk estimation of second primary cancers after breast radiotherapy.
Santos AM; Marcu LG; Wong CM; Bezak E
Acta Oncol; 2016 Nov; 55(11):1331-1337. PubMed ID: 27379458
[TBL] [Abstract][Full Text] [Related]
19. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field.
Paganetti H; Athar BS; Moteabbed M; A Adams J; Schneider U; Yock TI
Phys Med Biol; 2012 Oct; 57(19):6047-61. PubMed ID: 22968191
[TBL] [Abstract][Full Text] [Related]
20. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors.
Moteabbed M; Yock TI; Paganetti H
Phys Med Biol; 2014 Jun; 59(12):2883-99. PubMed ID: 24828559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
